Literature DB >> 18313654

Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells.

Ji Young Im1, Hyeyoung Park, Keon Wook Kang, Wahn Soo Choi, Hyung Sik Kim.   

Abstract

The histone deacetylase (HDAC) inhibitor, apicidin, has been shown to suppress the growth of human breast cancer cells. In this article, we examined the ability of apicidin to inhibit the proliferation of human breast cancer cell lines. Cell cycle regulators and apoptotic cell death were determined using Western blot analysis and DAPI fluorescence staining, respectively. Apicidin treatment produced significant increases in acetylated H3 and H4 levels. In MCF-7 cells, the expression of ERalpha and ERbeta was decreased in a dose-dependent manner after apicidin treatment. However, ERbeta expression was not changed in MDA-MB-231 cells. Apicidin (300 nM) significantly induced expression of p21Waf1 and p27Kip1. Expression levels of cell cycle regulator proteins (cyclin D1/CDK 4 and cyclin E/CDK 2) were markedly decreased by apicidin in MCF-7 cells, but not in MDA-MB-231 cells. Cell cycle analysis indicated that apicidin increased the proportion of cells in the G1 phase and decreased the proportion of cells in the S phase in MCF-7 cells. Significantly, increase in sub-G1 populations was observed in MCF-7 cells by apicidin treatment. Apicidin treatment resulted in the induction of apoptotic cell death which was confirmed by DAPI staining. Additionally, apicidin significantly increased the bax/bcl-2 ratio in MCF-7 cells. These results suggest that apicidin inhibits proliferation of ER-positive MCF-7 breast cancer cells by altering the expression of cell cycle regulator proteins and inducing apoptotic cell death. These distinctive cell-specific effects of apicidin on the modulation of cell cycle arrest and apoptosis may be associated with ERalpha-mediated transcriptional regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313654     DOI: 10.1016/j.cbi.2008.01.007

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  10 in total

1.  A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.

Authors:  Ji Hye Park; Mee Young Ahn; Tae Hyung Kim; Sungpill Yoon; Keon Wook Kang; Jaewon Lee; Hyung Ryong Moon; Jee H Jung; Hae Young Chung; Hyung Sik Kim
Journal:  Invest New Drugs       Date:  2011-10-08       Impact factor: 3.850

2.  Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.

Authors:  Maria Buoncervello; Paola Borghi; Giulia Romagnoli; Francesca Spadaro; Filippo Belardelli; Elena Toschi; Lucia Gabriele
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

3.  Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  Kennichi C Dowdell; Lesley Pesnicak; Victoria Hoffmann; Kenneth Steadman; Alan T Remaley; Jeffrey I Cohen; Stephen E Straus; V Koneti Rao
Journal:  Exp Hematol       Date:  2009-02-12       Impact factor: 3.084

4.  Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation.

Authors:  Yong Zhang; Donald Y M Leung; Steven K Nordeen; Elena Goleva
Journal:  J Biol Chem       Date:  2009-07-08       Impact factor: 5.157

5.  Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.

Authors:  Steffen Wedel; Lukasz Hudak; Jens-Michael Seibel; Jasmina Makarević; Eva Juengel; Igor Tsaur; Ana Waaga-Gasser; Axel Haferkamp; Roman A Blaheta
Journal:  BMC Cancer       Date:  2011-08-25       Impact factor: 4.430

Review 6.  Epigenetic therapy for breast cancer.

Authors:  Feng-Feng Cai; Corina Kohler; Bei Zhang; Ming-Hong Wang; Wei-Jie Chen; Xiao-Yan Zhong
Journal:  Int J Mol Sci       Date:  2011-07-11       Impact factor: 5.923

7.  HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review).

Authors:  Xuan Ni; Li Li; Guoyu Pan
Journal:  Oncol Lett       Date:  2014-11-19       Impact factor: 2.967

Review 8.  Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?

Authors:  Filipa Moreira-Silva; Vânia Camilo; Vítor Gaspar; João F Mano; Rui Henrique; Carmen Jerónimo
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

9.  Gamma Tocopherol Reduced Chemotherapeutic-Induced ROS in an Ovarian Granulosa Cell Line, But Not in Breast Cancer Cell Lines In Vitro.

Authors:  Daniela Figueroa Gonzalez; Fiona Young
Journal:  Antioxidants (Basel)       Date:  2020-01-07

10.  Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.

Authors:  Anssi Lipponen; Assam El-Osta; Antony Kaspi; Mark Ziemann; Ishant Khurana; Harikrishnan Kn; Vicente Navarro-Ferrandis; Noora Puhakka; Jussi Paananen; Asla Pitkänen
Journal:  Acta Neuropathol Commun       Date:  2018-02-27       Impact factor: 7.801

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.